Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1

Shu Wen Wan, Yi Tien Lu, Chia Hui Huang, Chiou Feng Lin, Robert Anderson, Hsiao Sheng Liu, Trai Ming Yeh, Yu Ting Yen, Betty A. Wu-Hsieh, Yee Shin Lin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Infection with dengue virus (DENV) may cause life-threatening disease with thrombocytopenia and vascular leakage which are related to dysfunction of platelets and endothelial cells. We previously showed that antibodies (Abs) against DENV nonstructural protein 1 (NS1) cross-react with human platelets and endothelial cells, leading to functional disturbances. Based on sequence homology analysis, the C-terminal region of DENV NS1 protein contains cross-reactive epitopes. For safety in vaccine development, the cross-reactive epitopes of DENV NS1 protein should be deleted or modified. Methodology/Principal Findings: We tested the protective effects of Abs against full-length DENV NS1, NS1 lacking the C-terminal amino acids (a.a.) 271-352 (designated DC NS1), and chimeric DJ NS1 consisting of N-terminal DENV NS1 (a.a. 1-270) and C-terminal Japanese encephalitis virus NS1 (a.a. 271-352). The anti-ΔC NS1 and anti-DJ NS1 Abs showed a lower binding activity to endothelial cells and platelets than that of anti-DENV NS1 Abs. Passive immunization with anti-ΔC NS1 and anti-DJ NS1 Abs reduced DENV-induced prolonged mouse tail bleeding time. Treatment with anti-DENV NS1, anti-ΔC NS1 and anti-DJ NS1 Abs reduced local skin hemorrhage, controlled the viral load of DENV infection in vivo, synergized with complement to inhibit viral replication in vitro, as well as abolished DENV-induced macrophage infiltration to the site of skin inoculation. Moreover, active immunization with modified NS1 protein, but not with unmodified DENV NS1 protein, reduced DENV-induced prolonged bleeding time, local skin hemorrhage, and viral load. Conclusions/Significance: These results support the idea that modified NS1 proteins may represent an improved strategy for safe and effective vaccine development against DENV infection.

Original languageEnglish
Article numbere92495
JournalPLoS One
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 21 2014
Externally publishedYes

Fingerprint

Dengue virus
Dengue Virus
Virus Diseases
Viruses
antibodies
Antibodies
mice
infection
Proteins
proteins
Protein C
hemorrhage
Bleeding Time
Endothelial cells
Blood Platelets
Endothelial Cells
Platelets
skin (animal)
Viral Load
endothelial cells

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1. / Wan, Shu Wen; Lu, Yi Tien; Huang, Chia Hui; Lin, Chiou Feng; Anderson, Robert; Liu, Hsiao Sheng; Yeh, Trai Ming; Yen, Yu Ting; Wu-Hsieh, Betty A.; Lin, Yee Shin.

In: PLoS One, Vol. 9, No. 3, e92495, 21.03.2014.

Research output: Contribution to journalArticle

Wan, SW, Lu, YT, Huang, CH, Lin, CF, Anderson, R, Liu, HS, Yeh, TM, Yen, YT, Wu-Hsieh, BA & Lin, YS 2014, 'Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1', PLoS One, vol. 9, no. 3, e92495. https://doi.org/10.1371/journal.pone.0092495
Wan, Shu Wen ; Lu, Yi Tien ; Huang, Chia Hui ; Lin, Chiou Feng ; Anderson, Robert ; Liu, Hsiao Sheng ; Yeh, Trai Ming ; Yen, Yu Ting ; Wu-Hsieh, Betty A. ; Lin, Yee Shin. / Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1. In: PLoS One. 2014 ; Vol. 9, No. 3.
@article{9f2f1b5d92ea42fd8666ece1b62e299b,
title = "Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1",
abstract = "Background: Infection with dengue virus (DENV) may cause life-threatening disease with thrombocytopenia and vascular leakage which are related to dysfunction of platelets and endothelial cells. We previously showed that antibodies (Abs) against DENV nonstructural protein 1 (NS1) cross-react with human platelets and endothelial cells, leading to functional disturbances. Based on sequence homology analysis, the C-terminal region of DENV NS1 protein contains cross-reactive epitopes. For safety in vaccine development, the cross-reactive epitopes of DENV NS1 protein should be deleted or modified. Methodology/Principal Findings: We tested the protective effects of Abs against full-length DENV NS1, NS1 lacking the C-terminal amino acids (a.a.) 271-352 (designated DC NS1), and chimeric DJ NS1 consisting of N-terminal DENV NS1 (a.a. 1-270) and C-terminal Japanese encephalitis virus NS1 (a.a. 271-352). The anti-ΔC NS1 and anti-DJ NS1 Abs showed a lower binding activity to endothelial cells and platelets than that of anti-DENV NS1 Abs. Passive immunization with anti-ΔC NS1 and anti-DJ NS1 Abs reduced DENV-induced prolonged mouse tail bleeding time. Treatment with anti-DENV NS1, anti-ΔC NS1 and anti-DJ NS1 Abs reduced local skin hemorrhage, controlled the viral load of DENV infection in vivo, synergized with complement to inhibit viral replication in vitro, as well as abolished DENV-induced macrophage infiltration to the site of skin inoculation. Moreover, active immunization with modified NS1 protein, but not with unmodified DENV NS1 protein, reduced DENV-induced prolonged bleeding time, local skin hemorrhage, and viral load. Conclusions/Significance: These results support the idea that modified NS1 proteins may represent an improved strategy for safe and effective vaccine development against DENV infection.",
author = "Wan, {Shu Wen} and Lu, {Yi Tien} and Huang, {Chia Hui} and Lin, {Chiou Feng} and Robert Anderson and Liu, {Hsiao Sheng} and Yeh, {Trai Ming} and Yen, {Yu Ting} and Wu-Hsieh, {Betty A.} and Lin, {Yee Shin}",
year = "2014",
month = "3",
day = "21",
doi = "10.1371/journal.pone.0092495",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1

AU - Wan, Shu Wen

AU - Lu, Yi Tien

AU - Huang, Chia Hui

AU - Lin, Chiou Feng

AU - Anderson, Robert

AU - Liu, Hsiao Sheng

AU - Yeh, Trai Ming

AU - Yen, Yu Ting

AU - Wu-Hsieh, Betty A.

AU - Lin, Yee Shin

PY - 2014/3/21

Y1 - 2014/3/21

N2 - Background: Infection with dengue virus (DENV) may cause life-threatening disease with thrombocytopenia and vascular leakage which are related to dysfunction of platelets and endothelial cells. We previously showed that antibodies (Abs) against DENV nonstructural protein 1 (NS1) cross-react with human platelets and endothelial cells, leading to functional disturbances. Based on sequence homology analysis, the C-terminal region of DENV NS1 protein contains cross-reactive epitopes. For safety in vaccine development, the cross-reactive epitopes of DENV NS1 protein should be deleted or modified. Methodology/Principal Findings: We tested the protective effects of Abs against full-length DENV NS1, NS1 lacking the C-terminal amino acids (a.a.) 271-352 (designated DC NS1), and chimeric DJ NS1 consisting of N-terminal DENV NS1 (a.a. 1-270) and C-terminal Japanese encephalitis virus NS1 (a.a. 271-352). The anti-ΔC NS1 and anti-DJ NS1 Abs showed a lower binding activity to endothelial cells and platelets than that of anti-DENV NS1 Abs. Passive immunization with anti-ΔC NS1 and anti-DJ NS1 Abs reduced DENV-induced prolonged mouse tail bleeding time. Treatment with anti-DENV NS1, anti-ΔC NS1 and anti-DJ NS1 Abs reduced local skin hemorrhage, controlled the viral load of DENV infection in vivo, synergized with complement to inhibit viral replication in vitro, as well as abolished DENV-induced macrophage infiltration to the site of skin inoculation. Moreover, active immunization with modified NS1 protein, but not with unmodified DENV NS1 protein, reduced DENV-induced prolonged bleeding time, local skin hemorrhage, and viral load. Conclusions/Significance: These results support the idea that modified NS1 proteins may represent an improved strategy for safe and effective vaccine development against DENV infection.

AB - Background: Infection with dengue virus (DENV) may cause life-threatening disease with thrombocytopenia and vascular leakage which are related to dysfunction of platelets and endothelial cells. We previously showed that antibodies (Abs) against DENV nonstructural protein 1 (NS1) cross-react with human platelets and endothelial cells, leading to functional disturbances. Based on sequence homology analysis, the C-terminal region of DENV NS1 protein contains cross-reactive epitopes. For safety in vaccine development, the cross-reactive epitopes of DENV NS1 protein should be deleted or modified. Methodology/Principal Findings: We tested the protective effects of Abs against full-length DENV NS1, NS1 lacking the C-terminal amino acids (a.a.) 271-352 (designated DC NS1), and chimeric DJ NS1 consisting of N-terminal DENV NS1 (a.a. 1-270) and C-terminal Japanese encephalitis virus NS1 (a.a. 271-352). The anti-ΔC NS1 and anti-DJ NS1 Abs showed a lower binding activity to endothelial cells and platelets than that of anti-DENV NS1 Abs. Passive immunization with anti-ΔC NS1 and anti-DJ NS1 Abs reduced DENV-induced prolonged mouse tail bleeding time. Treatment with anti-DENV NS1, anti-ΔC NS1 and anti-DJ NS1 Abs reduced local skin hemorrhage, controlled the viral load of DENV infection in vivo, synergized with complement to inhibit viral replication in vitro, as well as abolished DENV-induced macrophage infiltration to the site of skin inoculation. Moreover, active immunization with modified NS1 protein, but not with unmodified DENV NS1 protein, reduced DENV-induced prolonged bleeding time, local skin hemorrhage, and viral load. Conclusions/Significance: These results support the idea that modified NS1 proteins may represent an improved strategy for safe and effective vaccine development against DENV infection.

UR - http://www.scopus.com/inward/record.url?scp=84899123513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899123513&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0092495

DO - 10.1371/journal.pone.0092495

M3 - Article

C2 - 24658118

AN - SCOPUS:84899123513

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e92495

ER -